Three-drug combination active in pretreated multiple myeloma

ByAshley Killen

Fact checked byMindy Valcarcel, MS

NEW ORLEANS — A novel combination induced response among patients with pretreated multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.

The regimen — which consisted of teclistamab (JNJ-64007957, Janssen), subcutaneous daratumumab (Darzalex Faspro, Janssen) and lenalidomide (Revlimid, BMS) — also appeared well-tolerated, according to researchers.

Healio spoke with investigator Emma Searle, MBChB, MA, MRCP, FRCPath, PhD, consultant hematologist at The Christie Hospital NHS Foundation Trust and honorary senior lecturer at University of Manchester, about the study results and their potential implications.

Published by:

Sources/Disclosures

Collapse

Source:

Searle E, et al. Abstract 160. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Disclosures: Searle reports honoraria from AbbVie and Janssen, as well as an advisory role with Shattuck Labs.

ASH Annual Meeting and Exposition

Read more

Three-drug combination active in pretreated multiple myeloma

Related Content